Abiraterone acetate in castration-resistant prostate cancer
Anti-Cancer Drugs, 02/03/2012
Clinical Article
Iacovelli R et al. – This review focuses on abiraterone acetate, the first compound that, through the inhibition of adrenal gland production of testosterone, increases the overall survival in castration–resistant prostate cancer (CRPC) patients.






